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Abstract:  Epidemiological  studies  have  suggested  that  there  are  many  risk  factors 
associated  with  breast  cancer.  Silencing  tumor  suppressor  genes  through  epigenetic 
alterations play critical roles in breast cancer initiation, promotion and progression. As a 
growth  promoter,  Zeranol  (Z)  has  been  approved  by  the  FDA  and  is  widely  used  to 
enhance the growth of beef cattle in the United States. However, the safety of Z use as a 
growth promoter is still under debate. In order to provide more evidence to clarify this 
critical health issue, the current study investigated the effect of Z on the proliferation of 
primary cultured human normal and  cancerous breast epithelial cells  (PCHNBECs  and 
PCHBCECs, respectively) isolated from the same patient using MTS assay, RT-PCR and 
Western blot analysis. We also conducted an investigation regarding the mechanisms that 
might be involved. Our results show that Z is more potent to stimulate PCHBCEC growth 
than PCHNBEC growth. The stimulatory effects of Z on PCHBCECs and PCHBCECs 
may be mediated by its down-regulating expression of the tumor suppressor gene p53 at 
the mRNA and protein levels. Further investigation showed that the expression of DNA 
methylatransferase  1  mRNA  and  protein  levels  is  up-regulated  by  treatment  with  Z  in 
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PCHBCECs  as  compared  to  PCHNBECs,  which  suggests  a  role  of  Z  in  epigenetic 
modification  involved  in  the  regulation  of  p53  gene  expression  in  PCHBCECs.  Our 
experimental  results  imply  the  potentially  adverse  health  effect  of  Z  in  breast  cancer 
development. Further study is continuing in our laboratory. 
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1. Introduction 
Breast cancer remains a serious problem in the U.S. It is estimated that more than one-fourth of 
cancer  patients  were  breast  cancer  patients  in  2010  and  it  ranks  as  the  second  leading  cause  of  
cancer-related  deaths [1].  The  risk  factors  associated  with  breast  cancer  have  been  well  studied. 
Epidemiological studies suggest that there are many risk factors, such as dietary fat and environmental 
estrogenic endocrine disruptors. It has been reported that breast cancer cells express high levels of 
aromatase, which can convert androgens into estrogens, resulting in high concentrations of estrone (E1) 
and estradiol (E2) in breast tissue [2,3]. This finding might be the major reason for high risk of breast 
cancer in postmenopausal women and obese women.  
Zearalenone, a stable natural product that mimics estrogen activity, is carcinogenic and hazardous 
to human health [4]. It was reported that zearalenone may represent a growth promoter in exposed 
patients and there is a possible relationship between environmental mycoestrogen exposure and the 
development  of  central  precocious  puberty  [5].  Zeranol  (Z),  produced  from  zearalenone,  is  a  
non-estrogenic anabolic growth promoter and is widely used in the U.S. beef industry to accelerate 
weight  gain,  improve  feed  conversion  efficacy,  and  increase  the  lean  meat-to-fat  ratio  [6].  It  is 
approved  by  the  FDA  based  on  its  toxicity  information.  However,  the  potentially  adverse  health 
concerns associated with Z have caused the European Union (EU) to refuse the import of beef products 
with any growth promoter implantation from the U.S., resulting in a serious legal issue between the 
U.S. and the EU. We need greater concrete evidence to clarify this important health issue in order to 
bring awareness to the FDA.  
Both zearalenone and Z can bind to the active site of human estrogen receptor α (ER α) and ER β in 
a manner similar to 17β-estradiol [7]. As a food contaminant, the intake of Z is very hard to avoid [8]. 
It is still not clear whether Z and its metabolites cause any adverse health risks from consuming beef 
products produced from Z-implanted beef cattle. Researchers have found that low concentrations of Z 
can increase ER α-positive human breast cell growth, but a high concentration of Z can reduce growth 
of both ERα-positive and ER-negative cell lines [9]. Our previous data showed that Z was able to 
transform  normal  human  breast  epithelial  cells  and  increase  human  breast  cell  growth  in  a  
dose-dependent manner [10]. Z can also down-regulate the estrogen-regulated human breast cancer 
candidate suppressor gene, protein tyrosine phosphatase γ (PTPγ) expression [7]. Our laboratory’s 
recent  experimental  results  showed  that  pre-adipocytes  isolated  from  the  cattle  60  days  post  
Z-implantation (72 mg/pellets/animal) grow about 12-times faster than the pre-adipocytes isolated from 
control cattle [11]. Treatment with 0.2, 1 and 5% Z sera (ZS) harvested from the cattle 30 days post 
implantation in culture medium significantly stimulated MCF-10A and MCF-7 cell growth [12,13]. We Int. J. Mol. Sci. 2011, 12                    
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also have evidence showing that leptin, which plays a role in breast cancer development in obesity, induces 
human breast cancer epithelial cell sensitivity to Z [14].  
The relationship between the consumption of beef products with residue of Z and its metabolites 
and cancer development  is still in debate. However, epidemiology studies showed that the semen 
quality of fertile U.S. males is related to their mother’ beef consumption during their pregnancy [15]. It 
has been reported that higher red meat intake in adolescence may increase the risk of premenopausal 
breast  cancer  [16].  Early  in  1989,  Aw  and  colleagues  reported  that  workers  were  exposed  to  Z 
formulate pellets along with a package of animal growth promoter containing Z as its active ingredient 
in a small manufacturing plant. Their industrial exposure to Z caused one child to be afflicted with 
advanced bone aging due to his parents wearing their work clothes home (estimated 32 mg of Z on 
contaminated  work  clothes)  [17].  It  is  well-known  that  the  tumor  suppressor  gene  p53  plays  an 
important role in controlling cell life and death [18]. Loss of normal p53 function occurs in all types of 
human tumors, including breast cancer [19–21]. Baker and co-worker determined the p53 mutation 
status in 246 women with primary breast cancer and identified the p53 mutations in 26% of patients 
that  may  also  be  associated  with  poor  prognosis  [22].  It  is  estimated  that  at  least  one-third  of  
non-familial  breast  cancer  patients  bear  mutations  in  p53  [23].  Additionally,  mutation  of  p53  is 
correlated with heritable mutations in BRCA1 [24]. The mechanisms of regulating p53 expression in 
breast cancer cells have been well studied. Our previous investigation found that the pre-adipocytes 
derived from the heifer after two month of Z-implantation grew about 12-times faster than those from 
the control heifer. The expression of p53 mRNA and protein was also lower in the Z treated group than 
the control [11]. However, the function of growth promoter-Z on regulation of p53 in primary cultured 
human normal and cancerous breast epithelial cells is still unknown. 
Epigenetics is the study of nuclear inheritance that is not based on differences in DNA sequences, 
but the changes in DNA structure partially due to altered DNA methylation. DNA methyltransferase 1 
(DNMT1) is known to be a major DNA methyltransferase that can catalyze a methyl group in cytosine 
residues within CpG dinucleotides and lead to the tumor suppressor gene silencing [25–27]. CpG 
methylation in the p53 promoter region was detected in breast cancer [28]. Our investigation has 
centered around determining whether Z stimulates breast cancer cell lines as well as primary cultured 
human normal and cancerous breast epithelial cells mediated by regulating DNA methyltransferase 1 
(DNMT1) and hypermethylation in the promoter regions, thus resulting in the silencing of the tumor 
suppressor  gene,  p53 expression. The  current  study investigates  the  effect  of  Z  on  the  growth  of 
primary  cultured  human  normal  and  cancerous  breast  epithelial  cells  as  well  as  the  underlying 
mechanisms. Our results indicate that Z is more potent to stimulate primary culture human breast 
cancer epithelial cells (PCHBCECS) growth than primary culture human normal breast epithelial cells 
(PCHNBECS) and the stimulatory effects may be mediated by regulating the expression of DNMT1 
and down-regulating p53 expression in PCHBCECs but not in PCHNBECs. 
2. Results and Discussion 
2.1. Z Increases the Proliferation of PCHNBECs and PCHBCECs  
Our  previous  experimental  results  showed  that  Z  stimulates  MCF-7  cell  and  MCF-10A  cell 
growth [10]. The serum harvested from the heifer one month post Z implantation is more potent in Int. J. Mol. Sci. 2011, 12                    
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stimulating human breast cancer cell lines as well as PCHBCEC growth than that from control heifers. 
In the current study, we evaluated the effects of Z on PCHNBEC’s and PCHBCEC’s growth. The 
results show Z increased the proliferation of both PCHNBECs and PCHBCECs in a dose-dependent 
manner  (Figure  1).  PCHBCECs  are  more  sensitive  in  response  to  Z  treatment  than 
PCHNBECs (Figure 1). 
Figure  1.  Effects  of  zeranol  on  the  proliferation  of  PCHNBECs  and  PCHBCECs. 
PCHNBECs and PCHBCECs (5 ×  10
3 cells/well) were treated with 0.1% DMSO (as a 
vehicle control), 7.5, 15 and 30 nM zernaol in 96-well plates for 24 h. Non-radioactive cell 
proliferation assay was performed after 24 h treatment. Each bar represents the mean ±  SD 
of  4  replicate  wells.  The  asterisks  show  statistically  significant  differences  between  Z 
treatment groups and the control groups (p < 0.05). The figure illustrates that PCHBCECs 
are more sensitive to Z treatment than PCHNBECs. 
 
2.2. Regulatory Effects of Z on p53 mRNA and Protein Expression in PCHNBECs and PCHBCECs  
In  order  to  explore  the  possible  mechanisms  involved  in  Z  stimulation  of  PCHNBECs  and 
PCHBCECs proliferation, we examined the expression of the p53 gene at the mRNA and proteins 
level.  p53  is  involved  in  many  important  physiological  processes  such  as  cell  cycle  arrest,  gene 
transcription,  DNA  repair,  and  apoptosis.  Our  result  illustrated  that  Z  treatment  significantly 
suppressed the level of p53 mRNA and protein expression in PCHBCECs in comparison to the levels 
in the control group (Figures 2 and 4). However, Z did not show significant reduction of p53 mRNA 
and protein expression in PCHNBECs when compared to the control (Figure 2). 
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Figure 2. Comparison of effect of Z on the expression of p53 mRNA in PCHNBECs and 
PCHBCECs.  PCHNBECs  and  PCHBCECs  (1  ×   10
5  cells/well)  were  seeded  in  6-well 
plates and treated with 0.1% DMSO, 7.5, 15, and 30 nM Z. After 24 h treatment, total 
RNA was isolated from each treatment group and RNA concentrations were measured. 
Then, cDNA was synthesized and real time PCR was performed to amplify p53 and 36B4 
genes. The mRNA ratios of p53 to 36B4 were calculated using the ΔΔCt method. Each bar 
represents mean ±  SE of three independent experiment. The asterisks show statistically 
significant  differences  between  Z  treatment  groups  and  the  control  groups  (p  <  0.05). 
It shows  that  Z  decreases  the  expression  level  of  p53  mRNA  in  PCHBCECs  but  not 
in PCHNBECs. 
 
2.3. Z Regulates the Expression of DNMT1 mRNA and Protein in PCHNBECs and PCHBCECs 
DNMT1 plays an important role in silencing tumor suppressor genes, such as BRCA1, p16, and p21 
in breast cancer development. It was reported that DNMT1 is over-expressed in breast cancer [29,30]. 
To explore the possible mechanisms of Z regulating p53 gene expression, we investigated the effects 
of Z on DNMT1 mRNA and protein expression in PCHNBECs and PCHBCECs after 24 h treatment. 
The results are shown in Figures 3 and 4. It is illustrated that Z treatment significantly increased the 
expression of DNMT1 mRNA and protein levels in PCHBCECs in a dose-dependent manner when 
compared to the control. However, Z did not significantly increase the expression of DNMT1 mRNA 
and protein in PCHNBECs when compared to the control. Our results suggest that Z regulate the 
expression of p53 in PCHBCECs, maybe through its epigenetic modification.  
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Figure 3. Effects of Z on regulation of the expression of DNMT1 mRNA in PCHBCECs 
and PCHNBECs. The expression levels of DNMT1 mRNA were evaluated in PCHBCECs 
and PCHNBECs after treatment with vehicle control or 7.5–30 nM Z using real time PCR 
analysis. 36B4 was used as an internal control. The mRNA ratios of DNMT1 to 36B4 were 
calculated using the ΔΔ Ct method. The asterisks show statistically significant differences 
between Z treatment groups and the control groups (p < 0.05).  
 
Figure 4. Zeranol regulates the expression of p53 and DNMT1 proteins in PCHNBECs 
and PCHBCECs. PCHNBECs and PCHBCECs were seeded in 10 cm culture dishes at a 
density of 1 ×  10
6 cells/dish and then treated with 7.5, 15, 30 nM Z or 0.1% DMSO as a 
vehicle control for 24 h. Proteins were extracted from each treatment group and Western 
blot analysis was conducted. -actin was used to confirm equal loading of total proteins 
during SDS-PAGE. 
 
2.4. Discussion 
Breast cancer development occurs in multiple stages, which are triggered by the evolution of altered 
gene function. Many of the gene changes that disrupt their coding regions are involved in initiation, 
promotion  and  progression  [31].  P53  is  a  tumor  suppressor  gene  which  plays  a  crucial  role  in 
regulating  cell  growth  following  exposure  to  various  stress  stimuli.  It  induces  growth  arrest  or 
programmed cell death (apoptosis) and it also plays an important role in the control of cell cycle 
checkpoints. Research found that  p53 is  the most frequently mutated gene  in  human  cancers.  An 
estimated  15–60%  of  breast  cancers  contain  p53  mutations  [32]  and  loss  of  p53  occurs  in 
approximately 80% of colorectal tumors [33]. Consequently, its function has been extensively studied. 
It was reported that tumor cells with mutant p53 protein might be associated with poor prognosis [32].  Int. J. Mol. Sci. 2011, 12                    
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The tumor suppressor p53 can regulate both cell proliferation and apoptosis. An imbalance between 
cell  proliferation  and  apoptosis  results  in  a  rapid  increase  in  cell  number,  the  most  prominent 
characteristic  of  tumors.  Normal  breast  epithelial  cells  induce  p53-dependent  apoptosis  and  
p53-independent cell cycle arrest of breast cancer cells [34]. In addition, p53 was also expected to play 
an  important  role  in  cancer  treatment  with  its  mutation  predicting  a  substantially  worsened 
prognosis [33].  Several  retrospective  studies  have  suggested  p53  gene  mutation  as  an  adverse 
prognostic  indicator  in  breast  cancer  patients;  it  can  predict  early  recurrence,  sensitivity  to 
chemotherapy, and death in breast cancer patients [35].  
Recently, it is becoming understood that epigenetic events, or heritable changes in gene expression 
capacity without DNA sequence alterations, are also central to tumor progression. Understanding the 
differential  roles  of  regional  hypermethylation  and  global  hypomethylation  in  breast  cancer  will 
facilitate novel therapeutic approaches to breast cancer therapy. It was found that hypomethylation of 
the  global  genome  can  lead  to  genomic  instability  that  is  exemplified  by  misalignments,  DNA 
breakage, deletions and duplications during DNA replication [36].  
DNA methylation is one of the major epigenetic modifications in cancer development which has a 
long-standing relationship with gene inactivity and has been implicated as an important factor in gene 
silencing  [37,38].  In  humans  and  most  mammals,  DNA  methylation  is  the  only  known  natural 
modification of DNA and only affects cytosines at the 5’ position when it is followed by a guanosine, 
known as CpG dinucleotides. Depending on the cell types and tissue, 3–4 % of all cytosine residues in 
vertebrate  DNA  may  be  present  as  5-methylcytosine  and  approximately  70  to  80%  of  all  CpG 
dinucleotides in human DNA are methylated [39]. However, this methylation occurs primarily in areas 
where CpG density is low, or at repeat DNA sites. Most CpG islands, especially those located in 
promoter region of a specific gene, are completely unmethylated. Interestingly, fully methylated CpG 
islands are found only in the promoters of silenced alleles for selected imprinted autosomal genes and 
multiple silenced genes on the inactivated X-chromosomes of females [40]. It is well established that 
almost half of the tumor suppressor genes that cause familial cancers through germline mutations can 
be inactivated in association with promoter hypermethylation in sporadic cancers [41]. Huang and 
colleagues, using a novel DNA array based technique called differential methylation hybridization, 
performed a genome wide screen for hypermethylated CpG islands in a panel of breast cancer cell 
lines. They found that approximately  10% of CpG islands exhibited methylation in normal breast 
epithelial cells. In contrast, breast cancer cell lines show methylation at a considerably larger fraction 
of CpG islands (15–25%) [42]. In clinical research, it was reported that DNA methylation in serum of 
breast  cancer  patients  may  be  considered  as  an  independent  prognostic  marker  [43].  
Methylation-dependent  gene  silencing  is  now  thought  to  be  mediated  through  local  changes  in 
chromatin conformation that limit promoter accessibility [44]. 
DNA methyltransferases (DNMTs) are critical enzymes that regulate DNA methylation. DNMT1 is 
the most important one; the N-terminus of DNMT1 contains regions responsible for targeting the 
enzyme  to  replication  foci  [45],  as  well  as  for  discriminating  between  unmethylated  and  
hemi-methylated DNA [46]. Overexpression of all the DNMTs at the mRNA level has been shown for 
several cancers [47–49]. Conversely, a  mouse  model for colon cancer demonstrated that reducing 
DNMT1 expression and activity via hemizygous knockout of the gene and treatment with a DNMT1 
inhibitor greatly reduced the number of intestinal adenomas [50]. Similarly, Macleod and Szyf found Int. J. Mol. Sci. 2011, 12                    
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that transfection of a murine adrenocortical tumor cell line with DNMT1 antisense expression vectors 
resulted in general DNA hypomethylation, growth inhibition in vitro, and decreased tumorigenicity  
in vivo [51]. Our laboratory recently reported PTP γ expression was reduced in breast cancer cell lines, 
SK-Br-3 and MCF-7 cells, and it can be re-activated with the treatment of deoxy-5-azacytidine, a  
well-known DNMT1 inhibitor [52]. These results suggest that DNMT1 can be thought of as a new 
target for novel drug development. 
Our  data  indicated  that  24  h  Z  treatment  stimulated  both  PCHNBEC’s  and  PCHBCEC’s 
proliferation in a dose-dependent manner, and PCHBCECs were more sensitive to Z than PCHNBECs. 
Z increased the DNMT1 expression in PCHBCECs and decreased the p53 expression at both the 
mRNA and protein levels; however, no such effect was found in PCHNBECs, suggesting Z might be 
more harmful to cancer patients than normal and Z might have adverse health problem when cancer 
patients intake beef products produced by Z-implanted beef cattle containing Z or its metabolites. One 
of the mechanisms is due to the increase of DNMT1 and decrease of p53 expression. In addition, all 
our experimental data was collected from matched human breast tissues, which can provide better data 
for  analyzing  the  difference  between  PCHNBECs  and  PCHBCECs  with  the  same  treatment  of 
different concentrations of Z to decrease the possible influence of age, sex, medication, life style, etc. 
In summary, our data show PCHBCECs may be more sensitive to exposure to Z. The stimulatory 
effects of Z on PCHBCECs might be possible through down-regulation of the expression of the p53 
gene and up-regulation of DNMT1 mRNA and protein. This result suggests that suppressed expression 
of  the  p53  gene  in  PCHBCECs  might  be  mediated  through  its  epigenetic  modification.  Further 
investigation into this critical issue is in progress in our laboratory.  
3. Experimental Section 
3.1. Isolation of Primary Cultured Human Normal Breast Epithelial Cells (PCHNBECs) and Cancer 
Epithelial Cells (PCHBCECs)  
Human normal and cancerous breast tissues from the same patient were obtained through the Tissue 
Procurement  Program  of  The  Ohio  State  University  Comprehensive  Cancer  Center  Hospital  in 
Columbus, OH, USA. After tissues were transferred in our laboratory, they were minced and then 
digested using digestion buffer which consisted of phenol red-free high calcium Dulbecco’s modified 
Eagle’s  medium  and  Ham’s  F12  medium  (1:1)  (DMEM/F12)  (1.05  mM  CaCl2)  with  2%  Bovine 
Serum Albumin (BSA) (Invitrogen, Carlsbad, CA, USA) containing 10 ng/mL Cholera toxin (Sigma, 
St.  Louis,  MO,  USA),  6300  U/mL  Collagenase  (Invitrogen),  and  100  U/mL  Hyalurinidase 
(Calbiochem, Gibbstown, NJ, USA). After the mixture was incubated in a humidified incubator (5% 
CO2, 95% air, 37 ° C) overnight, the solution was transferred to a 50 mL tube and centrifuged at  
1200 rpm for 5 min. The upper layer containing pre-adipocytes and middle layer containing stromal 
cells were transferred to another 15 mL tube separately while the pellet containing epithelial cells 
remained in the tube. All the pellets were washed by DMEM/F12 medium with antibiotic-antimycotic 
(100 U/mL penicillin G sodium, 100 µ g/mL streptomycin sulfate and 0.25 µ g/mL amphotericin B) 
(Invitrogen) and centrifuged again. This wash procedure was repeated three times. The final pellet in 
the tube contains PCHBCECs or PCHNBECs. The pellet was then resuspended in 10 mL low calcium 
(0.04  mM  CaCl2)  DMEM/F12  medium  supplemented  with  10%  of  low  calcium  FBS  (Atlanta Int. J. Mol. Sci. 2011, 12                    
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Biologicals, Norcross, GA, USA) and then transferred into a T75 flask for culturing. The method and 
the  specific  cultural  medium  ensure  the  purity  of  PCHBCECs  or  PCHNBECs  isolated  from  
normal  or  cancerous  breast  tissues.  Our  lab  members  have  determined  the  purity  of  the  isolated 
primary  cultured  human  normal  and  cancerous  breast  epithelial  cells  or  stromal  cells  by  using  
immunocytochemistry [53]. 
3.2. PCHBCECs and PCHNBECs Culture 
The isolated PCHNBECs and PCHBCECs were cultured in 75 cm
2 culture flasks in a humidified 
incubator (5% CO2, 95% air, 37 ° C) with 10 mL low calcium (0.04 mM CaCl2) DMEM/F12 mixture 
(Atlanta  Biologicals,  Norcross,  GA,  USA)  supplemented  with  10%  of  Chelex-100  (Bio-Rad 
Laboratories, Richmond, CA, USA) treated FBS (Invitrogen). The low calcium DMEM/F12 medium 
was changed every two days [10]. This was done to ensure the purity of PCHNBECs and PCHBCECs. 
When  the  cells  grew  to  85–90%  confluence,  cells  were  washed  with  10  mL  of  calcium-  and 
magnesium-free Phosphate Buffered Saline (PBS, pH 7.3), and then trypsinized with 3 mL of 0.25% 
trypsin–5.3 mM EDTA (Invitrogen) for 5–8 min at 37 ° C. The trypsinization was stopped by addition 
of 10 mL of DMEM/F12 medium with 10% FBS. After centrifugation, the dissociated cells were 
resuspended in low calcium DMEM/F12 medium with 10% low calcium FBS and sub-cultured into  
75 cm
2 culture flasks at a ratio of 1 flask to 3 flasks. All experiments were conducted on primary 
cultured human normal breast epithelial cells not generated beyond the fourth passage. 
3.3. Cell Proliferation Assay (MTT Assay) 
A total volume of 100 µL medium containing 5000 PCHNBECs or PCHBCECs/well was seeded in  
96-well plates in low calcium DMEM/F12 medium and incubated at 37 °C  for 24 h. The following day, 
medium  was  replaced  by  100  µ L  low  calcium  DMEM/F12  supplemented  with  0.2%  BSA  and 
incubated at 37 °C  for another 24 h. After, the treatment of 7.5, 15, 30 nM Z was given for 24 h (0.1% 
DMSO to control group), the proliferation of PCHNBECs and PCHBCECs was measured by adding  
20  µ L  of  a  fresh  mixture  of  3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-phenyl)-2-(4-
sulfophenyl)-2H-tetrazolium  (MTS)  and  phenazine  methosulfate  (PMS)  (20:1)  solution  (Promega, 
Madison, WI, USA) to each well. After incubation at 37  ° C for 1–3 h, optical density were measured 
by kinetic microplate reader  (Molecular Devices  Cooperation, Menio Park,  CA, USA) at 490  nm 
wavelength and cell growth was compared.  
3.4. Cell Treatment, RNA Isolation and cDNA Synthesis 
A total of 1 ×  10
5 viable PCHNBECs and PCHBCECs/well were seeded in 6-well plates in 5 mL 
low  calcium  DMEM/F12  medium  supplemented  with  10%  of  Chelex-100  (Bio-Rad  Laboratories, 
Hercules, CA, USA) treated FBS (Invitrogen). After 24 h, medium was replaced with low calcium 
DMEM/F12 supplemented with 10% dextran coated charcoal (DCC) stripped FBS, and the cells were 
cultured overnight. After PCHNBECs and PCHBCECs were treated with 0.1% DMSO, 7.5, 15 and 
30 nM Z for 24 h, total RNA was isolated in 1 mL TRIZOL Reagent (Invitrogen) according to the 
manufacturer’s  instructions.  RNA  concentration  was  measured  by  DU-70  spectrophotometer 
(Beckman  Instruments  Inc.  Fullerton,  CA,  USA).  RNA  (1  µ g)  from  cultured  cells  was  reverse Int. J. Mol. Sci. 2011, 12                    
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transcribed with 200 UM-MLV Reverse Transcriptase (Invitrogen) at 37 ° C for 50 min then 70 ° C for 
15 min in the presence of 1 µ L 10 mM dNTP (10 mM each dATP, dGTP, dCTP, and dTTP at neutral 
PH) (Invitrogen), 1 µ L 50 µ M Random hexamer (Amersham, Piscataway, NJ, USA), 10 µ L 5×  First 
Strand buffer, 5 µ L 0.1 M DTT and 1 µ L RNase Inhibitor (Invitrogen) in a total volume of 50 µL in a 
gradient mastercycle (Eppendorf
®, Westbury, NY, USA). 
3.5. Real Time PCR 
After cDNA was synthesized, real-time PCR was conducted to amplify p53, DNMT1 and 36B4 
genes.  The  PCR  reactions  for  p53,  DNMT1  and  36B4  were  performed  using  the  SYBR  Green  I 
detection chemistry system and detected with the Stratagene M3005XP system (Agilent Technologies, 
Cedar Creek, TX, USA). For each PCR run, a mixture contained 10 µ L 2×  SYBR
® Green PCR master 
mix (Applied Biosystems, Foster City, CA, USA), 2µ L newly synthesized cDNA, 5µ L primer mixer 
and 3µ L PCR grade water in a total volume of 20 µ L. The thermal cycling condition comprised an 
initial step at 50 ° C for 2 min, 95 ° C for 10 min, and 45 cycles at 95 ° C for 15 s and annealing and 
elongation at 55 ° C for 1 min. Dissociation curves were also conducted after amplification to ensure 
the reaction specificity. The primer sequences for p53 were 5’-GCT CCT GTG CTG CGA AGT GG-3’ 
(sense) and 5’-TGG AGG CGT CGG TGT AGA TG-3’ (antisense, product size 372 bp). The primer 
sequences for DNMT1 were 5’-CAT TTT ATC CCC ATT GAG AAG TA-3’ (sense) and 5’-CTG 
AAA ATT AAG TCC TTG TGC CCA G-3’ (antisense, product size 273 bp). The primer sequences 
for 36B4, an internal control were 5’-AAA CTG CTG CCT CAT ATC CG-3’ (sense) and 5’-TTT 
CAG CAA GTG GGA AGG TG-3’ (antisense, product size 563 bp). The results were presented as the 
ratio of p53 or DNMT1 to 36 B4.  
3.6. Western Blotting Assay  
PCHBCECs and PCHNBECs were plated in a 10 cm culture dish with a density of 1 ×  10
6 viable 
cells/dish within 10 mL low calcium DMEM/F12 supplement with 10% FBS and cultured overnight. 
The media was replaced with low calcium DMEM/F12 supplemented with 5% DCC treated FBS and 
was cultured for another 24 h. PCHBCECs and PCHNBECs treatment were the same as previously 
described. After 24 h treatment, proteins were extracted from each treatment group using M-PER
® 
mammalian protein extraction reagent (Pierce, Rockford, IL, USA) according to the manufacturer’s 
instructions. Protein concentrations were measured using a Micro BCA
TM protein assay reagent kit 
(Pierce,  Rockford,  IL,  USA)  following  the  manufacturer’s  protocol.  Proteins  (50  µ g)  from  each 
treatment  group  were  separated  by  4–15%  Tris-HCl  gel  electrophoresis  and  then  transferred  to  a 
Polyvinylidine  Fluoride  (PVDF)  membrane  (Bio-Rad  Laboratory,  Hercules,  CA,  USA).  The 
membrane was first blocked in Phosphate Buffered Saline −0.1% Tween 20 (PBST) containing 10% 
fat free dry milk for 1 h and then incubated with DNMT1 goat polyclonal antibody (dilution 1:500,  
sc-10219, Santa Cruz Biotechnology, Inc. Santa Cruz, CA, USA), p53 antibody (1:1000 dilution, Cell 
Signaling  Technology
®  Danvers,  MA,  USA)  and  β-actin  antibody  (1:2000  dilution,  Santa  Cruz 
Biotechnology, Inc.) for 1 h. The membrane was rinsed in PBST three times, each time for 5 min. In 
the  following  step,  the  membrane  was  incubated  with  second  antibody  (donkey  anti-goat  
IgG-horseradish peroxidase HRP for DNMT1 and β actin; ECLTM anti-rabbit IgG-HRP for detecting Int. J. Mol. Sci. 2011, 12                    
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p53) for 1 h. After washing the membrane in PBST three times, p53, DNMT1, and -actin protein 
were  visualized  with  a  chemiluminescent  detection  system  (ECL,  Amersham  Pharmacia  Biotech, 
Buckinghamshire, UK). Pictures were taken using a FujiFilm LAS-300 imaging system (FUJIFILM 
Medical  Systems  USA,  Inc.).  The  protein  ratios  of  p53  to  β-actin  and  DNMT1  to  β-actin  were 
calculated by measuring the density of the specific band using Multi-Gauge software (v3.0).  
3.7. Statistical Analysis 
The  results  for  the  cell  proliferation  assay  are  presented  compared  to  the  control  group  as  
mean ±  standard deviation (SD) for 4 replicate culture wells. The results for the mRNA expression are 
presented compared to the control group as mean ±  standard deviation (SD) for 3 replicates. Analyses 
were  performed  using  Minitab  15  software  (Minitab  Inc.  PA,  USA).  Statistical  differences  were 
determined by using two sample t-test or ANOVA analysis for independent samples. P-values of less 
than 0.05 were considered statistically significant differences. 
4. Conclusions 
Our experimental results demonstrated that the growth promoter Z stimulates the proliferation of 
PCHBCECs. The stimulatory effects of Z on the cells may be mediated by down-regulating the tumor 
suppressor gene p53 at the mRNA and protein levels. Further investigation illustrated that the DNA 
methylatransferase 1 mRNA and protein levels were up-regulated by the treatment of Z in PCHBCECs 
as compared to PCHNBECs, which suggests a role of Z in epigenetic modification involved in the 
regulation of p53 gene expression in PCHBCECs. Our experimental results imply the potential adverse 
health effect of Z in breast cancer development. Further study is under process in our laboratory 
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